Patient and Oncologist Preferences for ALK plus Advanced Non-Small Cell Lung Cancer Tyrosine Kinase Inhibitor Treatments

被引：0
|
作者：
Le, H. [1 ]
Coulter, J. [2 ]
Cappelleri, J. C. [2 ]
Lu, H. [3 ]
Quaife, M. [3 ]
Meginnis, K. [3 ]
Fernandez, G. [3 ]
Culver, K. [4 ]
Vaghela, S. [2 ]
Rifi, N. [2 ]
Stinchcombe, T. [5 ]
机构：
[1] Pfizer Inc, Fairfax, VA USA
[2] Pfizer Inc, New York, NY USA
[3] Evidera, Cambridge, England
[4] ALK Posit, Atlanta, GA USA
[5] Duke Hlth, Durham, NC USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
Preference; ALK; TKI;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.12B.05
引用
收藏
页码：S202 / S202
页数：1
相关论文
共 50 条
  • [31] Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment
    Ohtaki, Yoichi
    Shimizu, Kimihiro
    Suzuki, Hiroyuki
    Suzuki, Kenji
    Tsuboi, Masahiro
    Mitsudomi, Tetsuya
    Takao, Motoshi
    Murakawa, Tomohiro
    Ito, Hiroyuki
    Yoshimura, Kenichi
    Okada, Morihito
    Chida, Masayuki
    LUNG CANCER, 2021, 153 : 108 - 116
  • [32] Development of crizotinib, a rationally designed tyrosine kinase inhibitor for non-small cell lung cancer
    Poon, Candice C.
    Kelly, John J.
    INTERNATIONAL JOURNAL OF CANCER, 2017, 140 (09) : 1945 - 1954
  • [33] The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies
    Nikolinakos, Petros
    Heymach, John V.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S131 - S134
  • [34] Responses to ALK Inhibitor Treatments in a Patient with Non-Small Cell Lung Cancer Harboring a Novel HPCALI-ALK Fusion Variant: A Case Report
    Wang, Ruixiao
    Qin, Jiayue
    Fan, Yafeng
    Li, Zhimin
    Chen, Chongjian
    Su, Wenzhong
    ONCOTARGETS AND THERAPY, 2020, 13 : 4183 - 4187
  • [35] Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer
    Cameron, L. B.
    Hitchen, N.
    Chandran, E.
    Morris, T.
    Manser, R.
    Solomon, B. J.
    Jordan, V
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2022, (01):
  • [36] Lorlatinib experience in a patient with ALK plus non-small cell lung cancer on hemodialysis: A case report
    Gurbuz, Ali Fuat
    Eryilmaz, Melek Karakurt
    Yildiz, Oguzhan
    Kaya, Bahattin Engin
    Araz, Murat
    Artac, Mehmet
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 160 - 163
  • [37] Clinical outcomes of ALK plus non-small cell lung cancer in Denmark
    Hansen, Karin Holmskov
    Johansen, Jakob Sidenius
    Urbanska, Edyta Maria
    Meldgaard, Peter
    Hjorth-Hansen, Peter
    Kristiansen, Charlotte
    Stelmach, Miroslaw
    Santoni-Rugiu, Eric
    Ulhoi, Maiken Parm
    Dydensborg, Anders Bondo
    Dunweber, Christina
    Andersen, Jon Lykkegaard
    ACTA ONCOLOGICA, 2023, 62 (12) : 1775 - 1783
  • [38] Alectinib Optimal Dose in ALK plus Non-Small Cell Lung Cancer
    不详
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (06) : 1416 - 1416
  • [39] Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases
    Thomas, Christan M.
    Lee, Chung-Shien
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (03) : 623 - 637
  • [40] A rare case of non-small cell lung cancer choroidal metastasis responding to ALK tyrosine kinase inhibitors
    Scotti, Vieri
    Perna, Marco
    Meacci, Fiammetta
    Maragna, Virginia
    Garlatti, Pietro
    Vicini, Giulio
    Pieretti, Giulia
    Agresti, Benedetta
    Mazzini, Cinzia
    Livi, Lorenzo
    ANTI-CANCER DRUGS, 2020, 31 (01) : 90 - 94
12345